Skip to main content
. Author manuscript; available in PMC: 2014 Sep 18.
Published in final edited form as: Pediatr Pulmonol. 2011 Sep 8;47(3):252–263. doi: 10.1002/ppul.21546

TABLE 5.

Glucose Homeostasis: FPG, Fasting Insulin, and HOMA-IR (Mean ± SD)

Control Group rhGH-Treated Group
Visit
(n)		 Screening
(n = 27)		 Month 12
(n = 27)		 Month 18
(n = 25)		 Screening
(n = 35)		 Month 12
(n = 27)		 Month 18
(n = 23)
FPG, mg/mL 87.2 ± 8.3 88.9 ± 13.3 92.1 ± 9.8 87.1 ± 9.7 90.0 ± 11.81 87.3 ± 8.22
Fasting insulin, μU/mL 3.4 ± 2.5 7.4 ± 8.23 6.2 ± 5.3 4.1 ± 3.4 7.1 ± 4.04 5.1 ± 2.25,6
HOMA-IR 0.7 ± 0.6 1.8 ± 2.6 1.4 ± 1.2 0.9 ± 0.8 1.0 ± 0.3 1.1 ± 0.5

FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment of insulin resistance; rhGH, recombinant human growth hormone; SD, standard deviation.

Differences in the n value is consistent with subjects at screening, versus those in which fasting blood sugar and insulin levels were obtained at the 12- and 18-month visits.

1

Change from the screening to Month-12 visit was significantly increased, with p = 0.047.

2

Change from the Month-12 to Month-18 visit was significantly decreased, p = 0.034.

3

Change from the screening to Month-12 visit was significantly increased, with p = 0.016.

4

Change from the screening to Month-12 visit was significantly increased, with p = 0.002.

5

Change from the Month-12 to Month-18 visit was significantly decreased, p = 0.007.

6

Fasting insulin concentrations were significantly greater in control subjects versus rhGH subjects, p = 0.004.